Soligenix Announces Extended Stability of Ebolavirus Vaccines Using ThermoVax Platform

Soligenix has demonstrated two-year stability of ebolavirus vaccines using its ThermoVax platform. The bivalent and trivalent vaccines, formulated in a single vial, were stored at up to 40°C for two years and showed unchanged potency. The study's findings support the potential for long-term storage and distribution of ebolavirus vaccines.

Soligenix, Inc. (Nasdaq: SNGX) has announced significant progress in the stability of its ebolavirus vaccines, demonstrating two years of stability at high temperatures. The company's ThermoVax® platform has successfully thermostabilized vaccines for ricin toxin, filoviruses such as Ebola, Sudan, and Marburg, and COVID-19. The latest study, conducted in collaboration with Axel Lehrer, PhD, Professor at the John A. Burns School of Medicine, University of Hawaiʻi at Mānoa, shows that bivalent and trivalent vaccines, formulated in a single vial, retained their potency after two years of storage at up to 40°C (104°F) [1].

The study, titled "Thermostable Bivalent & Trivalent Filovirus Vaccines from Insect Cells: Potency Demonstrated after 3 Months and 2 Years," was accepted for publication in the Vaccine journal. The vaccines, constructed from antigens against Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus, as well as the CoVaccine HT™ antigen, were subjected to long-term storage and showed no change in potency. This extended stability is particularly relevant for the use of these vaccines in virus-endemic countries in Africa, as well as in the context of strategic national stockpiles and preparations for potential larger outbreaks and pandemics [1].

Soligenix's ThermoVax® platform offers a significant advantage over other vaccine technologies by enabling long-term storage at ambient temperatures. This simplification in storage and distribution logistics could significantly improve vaccination efforts globally. Moreover, the use of subunit vaccines that have been built on years of proven vaccine technology may provide a very safe option for people of all ages [1].

The company's focus on developing and commercializing products to treat rare diseases where there is an unmet medical need aligns with its mission to improve global health. The demonstration of two-year stability for ebolavirus vaccines underscores the potential of Soligenix's proprietary heat stabilization technology to enhance the long-standing protein subunit vaccination technology, making it competitive with other vaccine technologies [1].

References:
[1] https://www.marketscreener.com/news/soligenix-announces-publication-describing-long-term-high-temperature-stability-of-protein-subunit-v-ce7d59d8d88bf32c